EZH2 and adenoma: Consistent with the genetic ablation of Ezh2, we observed a dramatic decrease in the induction of mammary hyperplasias and early adenomas (Supplementary Figure 2B) and a complete block in the formation of lung metastases in GSK-126-treated cohorts (Fig. 2b).